Sevelamer carbonate 

Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes^{[1][2][3][4][5][6][7][8]}.

Sevelamer carbonate exhibits pH-dependent, reversible binding of AGE-BSA, with >80% binding at intestinal pH (7.0) and less than 5% binding at stomach pH (1.0), while showing minimal binding to unmodified BSA^[6].
Sevelamer (15 mg/mL; pH=6 or 8) carbonate decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL)^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sevelamer carbonate produces a dose-dependent reduction in urinary phosphate excretion of up to 96% in rats with normal renal function, with greater faecal phosphate excretion than calcium carbonate^[1].
Sevelamer carbonate improves renal function in a rat model of long-term uraemia by reducing renal calcification^[1].
Sevelamer (1% mixed in diet; p.o.; 2-3 weeks) carbonate does not alter serum phosphate levels in uremic WT mice, but further decreased serum phosphate levels in uremic Npt2b / mice in uremic mouse model^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

[(C₃H₇N)a+b·(C₉H₁₈N₂O)c]n·xH₂CO₃

845273-93-0

Solid

White to light yellow

NCC(CC(CC)CNCC(O)CNCC(C)CC(CC)CN)CC.[n].[c].[b].[a].[x H2CO3]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

• [1]. Henderson J, et al. Sevelamer. Nephron Clin Pract. 2003;94(3):c53-c58.  [Content Brief]

  [2]. Chertow GM, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252.  [Content Brief]

  [3]. Tonelli M, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22(10):2856-2866.  [Content Brief]

  [4]. Block GA, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005 Oct;68(4):1815-24.  [Content Brief]

  [5]. Chue CD, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24(5):842-852.  [Content Brief]

  [6]. Vlassara H, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934-942.  [Content Brief]

  [7]. Bennis Y, et al. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Toxins (Basel). 2019 May 17;11(5):279.  [Content Brief]

  [8]. Susan C Schiavi, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012 Oct;23(10):1691-700.  [Content Brief]